COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab.

Eileen B Doyle Darren J Bentley Michael G Dodds

Published in: British journal of clinical pharmacology (2021)

Coadministration of both IL-6 and IL-6R sequestering products such as SIL and TCZ may be necessary to effectively treat COVID-19 patients who have or are at risk of developing ARDS.

Keyphrases

acute respiratory distress syndrome
combination therapy
extracorporeal membrane oxygenation
sars cov
mechanical ventilation
coronavirus disease
rheumatoid arthritis
juvenile idiopathic arthritis
respiratory syndrome coronavirus
intensive care unit